Literature DB >> 28218620

Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia.

Vincent Hayes, Ian Johnston, Gowthami M Arepally, Steven E McKenzie, Douglas B Cines, Lubica Rauova, Mortimer Poncz.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by antibodies against complexes between human platelet factor 4 (hPF4) and heparin. A better understanding of the events that initiate the prothrombotic state may improve approaches to antithrombotic management. Here, we visualized thrombus formation in an in vivo murine model and an endothelialized microfluidic system that simulate the pathogenesis of HIT. hPF4 released from platelets predominantly bound to peri-injury endothelium and formed HIT antigenic complexes that were dissociated by heparin. In mice expressing both hPF4+ and human platelet IgG Fc receptor IIA (FcγRIIA), infusion of the HIT-like monoclonal antibody KKO increased fibrin and platelet deposition at sites of injury, followed immediately by antigen formation on proximate endothelial cells. After a few minutes, HIT antigen was detected within the thrombus itself at the interface between the platelet core and the surrounding shell. We observed similar results in the humanized, endothelialized microfluidic system. hPF4 and KKO selectively bound to photochemically injured endothelium at sites where surface glycocalyx was reduced. These studies support the concept that the perithrombus endothelium is the predominant site of HIT antigen assembly. This suggests that disrupting antigen formation along the endothelium or protecting the endothelium may provide a therapeutic opportunity to prevent thrombotic complications of HIT, while sparing systemic hemostatic pathways.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28218620      PMCID: PMC5330743          DOI: 10.1172/JCI90958

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

2.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

3.  The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).

Authors:  Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

4.  End of the road for heparin thromboprophylaxis.

Authors:  Lori-Ann Linkins
Journal:  Blood       Date:  2016-04-21       Impact factor: 22.113

5.  Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4.

Authors:  F Petersen; E Brandt; U Lindahl; D Spillmann
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

Review 6.  Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases.

Authors:  Bernhard F Becker; Matthias Jacob; Stephanie Leipert; Andrew H J Salmon; Daniel Chappell
Journal:  Br J Clin Pharmacol       Date:  2015-05-22       Impact factor: 4.335

Review 7.  Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia.

Authors:  Friedrich-Christian Riess
Journal:  Semin Thorac Cardiovasc Surg       Date:  2005

8.  Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition.

Authors:  John G Kelton; Marcie J Hursting; Nancy Heddle; Bruce E Lewis
Journal:  Blood Coagul Fibrinolysis       Date:  2008-09       Impact factor: 1.276

9.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

10.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more
  16 in total

1.  Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Authors:  Kandace Gollomp; Minna Kim; Ian Johnston; Vincent Hayes; John Welsh; Gowthami M Arepally; Mark Kahn; Michele P Lambert; Adam Cuker; Douglas B Cines; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  JCI Insight       Date:  2018-09-20

2.  Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation.

Authors:  Ian Johnston; Amrita Sarkar; Vincent Hayes; Gavin T Koma; Gowthami M Arepally; Junmei Chen; Dominic W Chung; José A López; Douglas B Cines; Lubica Rauova; Mortimer Poncz
Journal:  Blood       Date:  2020-04-09       Impact factor: 25.476

Review 3.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

Review 4.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

5.  Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.

Authors:  Kandace Gollomp; Amrita Sarkar; Sanjiv Harikumar; Steven H Seeholzer; Gowthami M Arepally; Kristin Hudock; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2020-03-05       Impact factor: 25.476

6.  Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia.

Authors:  Jing Dai; Daria Madeeva; Vincent Hayes; Hyun Sook Ahn; Valerie Tutwiler; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2018-06-18       Impact factor: 25.476

7.  FcRn augments induction of tissue factor activity by IgG-containing immune complexes.

Authors:  Douglas B Cines; Sergei Zaitsev; Lubica Rauova; Ann H Rux; Victoria Stepanova; Sriram Krishnaswamy; Amrita Sarkar; M Anna Kowalska; Guohua Zhao; Alan E Mast; Laurence J Blumberg; Keith R McCrae; Mortimer Poncz; Jonathan J Hubbard; Michal Pyzik; Richard S Blumberg
Journal:  Blood       Date:  2020-06-04       Impact factor: 22.113

8.  Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.

Authors:  Sanjay Khandelwal; Ayiesha Barnes; Lubica Rauova; Amrita Sarkar; Ann H Rux; Serge V Yarovoi; S Sergei Zaitsev; John D Lambris; Sooho S Myoung; Alexandra Johnson; Grace M Lee; Madelaine Duarte; Mortimer Poncz; Gowthami M Arepally; Douglas B Cines
Journal:  Blood       Date:  2021-11-25       Impact factor: 22.113

9.  Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin.

Authors:  Satish Maharaj; Simone Chang; Karan Seegobin; James Morales; Agnes Aysola; Fauzia Rana; Marwan Shaikh
Journal:  Exp Hematol Oncol       Date:  2018-09-14

10.  Fatty-Acid Uptake in Prostate Cancer Cells Using Dynamic Microfluidic Raman Technology.

Authors:  Nga-Tsing Tang; Richard D Snook; Mick D Brown; Bryan A Haines; Andrew Ridley; Peter Gardner; Joanna L Denbigh
Journal:  Molecules       Date:  2020-04-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.